Accumulating evidence points to the causal role of triglyceride-rich lipoproteins and their
cholesterol-enriched remnants in atherogenesis. Genetic studies in particular have not only …

Hypertriglyceridaemia is a common clinical problem. Epidemiologic and genetic studies
have established that triglyceride-rich lipoproteins (TRL) and their remnants as important …

Severe hypertriglyceridemia (sHTG) is an established risk factor for acute pancreatitis.
Current therapeutic approaches for sHTG are often insufficient to reduce triglycerides and …

Background Volanesorsen is an antisense oligonucleotide that targets hepatic
apolipoprotein C-III synthesis and reduces plasma triglyceride concentration. The aim of this …

Lipid disorders involving derangements in serum cholesterol, triglycerides, or both are
commonly encountered in clinical practice and often have implications for cardiovascular …

Hypertriglyceridemia, a commonly encountered phenotype in cardiovascular and metabolic
clinics, is surprisingly complex. A range of genetic variants, from single-nucleotide variants …

Genome sequencing and gene-based therapies appear poised to advance the
management of rare lipoprotein disorders and associated dyslipidaemias. However, in …

Several new or emerging drugs for dyslipidemia owe their existence, in part, to human
genetic evidence, such as observations in families with rare genetic disorders or in …

Hypertriglyceridemia (HTG) is a metabolic disorder, defined when serum or plasma
triglyceride concentration (seTG) is> 1.7 mM. HTG can be categorized as mild to very severe …

Abstract Purpose of Review Hypertriglyceridemia is a common dyslipidemia associated with
an increased risk of cardiovascular disease and pancreatitis. Severe hypertriglyceridemia …